Welcome to another edition of Contract Pharma’s Top Companies Report, where we rank the Top 25 Pharma and Biopharma firms based on 2018 revenues. In addition to the revenue rankings, each profile offers a snapshot of company highlights from the year along with a current view of pipeline info—from early research projects through to phase III and beyond—as well as a listing of top selling product performers in each company porfolio.

In 2018 combined sales of the Top 25 Pharma & Biopharma Companies profiled in our report totaled $614 billion, which was up from last year’s $599 billion mark. Fourteen of the top 25 companies reported positive growth. With 18%, 16%, 12% and 10% revenue hikes respectively, Celgene, AbbVie, Roche and Biogen achieved the most gains and were this year’s only double-digit revenue growth generators. At the same time, Teva and Gilead witnessed the largest fall off in sales from the previous year at 16% and 15% respectively.

I’d like to give a quick shout out to the folks over at research firm Evaluate for providing this year’s pipeline information. A brief meeting at a recent tradeshow turned into a successful partnership. You can learn more about them at Evaluate.com.

This year’s coverage begins here. Hope you enjoy!

Tim Wright, Editor
twright@rodmanmedia.com


2019 TOP PHARMA & BIOPHARMA CO’s
01. Pfizer   (prev.: 01)
02. Novartis   (prev.: 06)
03. Roche   (prev.: 02)
04. J&J   (prev.: 04)
05. Sanofi   (prev.: 03)
06. Merck & Co.  (prev.: 05)
07. AbbVie   (prev.: 08)
08. GSK   (prev.: 07)
09. Lilly   (prev.: 10)
10. Amgen   (prev.: 11)
11. BMS   (prev.: 14)
12. Gilead   (prev.: 09)
13. AstraZeneca  (prev.: 12)
14. Bayer   (prev.: 15)
15. Teva   (prev.: 13)
16. Novo Nordisk  (prev.: 16)
17. Takeda   (prev.: 17)
18. Allergan   (prev.: 18)
19. Celgene   (prev.: 21)
20. Boehringer-Ing  (prev.: 19)
21. Biogen   (prev.: 22)
22. Astellas   (prev.: 23)
23. Otsuka   (prev.: 25
24. Mylan   (prev.: 24)
25. Daiichi Sankyo  (prev.: n/a)